Compare Extra Space Storage, Inc. (EXR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Novo Nordisk A/S — how do they compare? Extra Space Storage, Inc. trades at $147.16 (market cap $30.96B), while Novo Nordisk A/S trades at $46.21 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 6.7× Extra Space Storage, Inc.'s market cap, and Extra Space Storage, Inc. pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| EXR | NVO | |
|---|---|---|
Market Cap | $30.96B | $207.85B |
Sector | Real Estate | Health |
52-Week High | $152.85 | $63.98 |
52-Week Low | $126.67 | $35.29 |
Enterprise Value | $44.68B | $222.55B |
Dividend Yield | 4.42% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXR trades at $147.22, up 0.38% today, near its 52-week high with a consensus price target of $157.25. The stock shows strong fundamentals, with Q2 2026 EPS beating estimates and a dividend yield supported by robust cash flow. Technicals are bearish on moving averages but neutral on oscillators, with key resistance at $148. Revenue growth has been steady, and the company maintains high profitability margins.
Outlook is positive with consistent earnings beats and a solid balance sheet, though high valuation multiples and competitive pressures pose risks. Analysts are mixed with a 'Hold' consensus, but institutional interest remains strong. The stock offers growth potential but requires monitoring of debt levels and market sentiment shifts.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
